International Journal of Engineering & Scientific Research
Vol.10 Issue 12, Dec 2022
ISSN: 2347-6532 Impact Factor: 6.660
Journal Homepage: http://www.ijmra.us, Email: editorijmie@gmail.com
Double-Blind Peer Reviewed Refereed Open Access International Journal - Included in the International Serial Directories Indexed & Listed at: Ulrich's Periodicals Directory ©, U.S.A., Open J-Gage as well as in Cabell's Directories of Publishing Opportunities, U.S.A

ADVANCES IN DRY EYE DISEASE: INFLAMMATION, OSMOLARITY, AND EMERGING THERAPIES

Dr Rakesh Sharma, Senior Resident
Department of Ophthalmology
Regional Institute of Ophthalmology, Government Medical College
Amritsar, Punjab, India

1.1. Abstract

Dry Eye Disease (DED) is a multi-factorial disease mostly involving the ocular surface and also affecting the visual status of patients profoundly as well as their functioning in their everyday life. The features of DED are the instability and hyperosmolarity of the tear film that stimulate a cascade of related inflammatory processes finally resulting in the corrosion of the ocular surface. Its prevalence rate is about 5-50 percent of the whole world population, and its prevalence continues to grow as it is exposed to age, screens, and the environment (Stapleton et al., 2017). Despite the conventional treatment that targets to treat the condition on a symptomatic basis through the use of artificial tears, the alternatives do not address the causative factors of the condition. Inflammation and tear osmolarity in DED progression have also become a new fact of development, and a tendency exists to apply special treatment. At the same time, excessive tears osmolarity results in apoptosis of the epithelial cells and, also, in neurons dysfunction. Variations in diagnosis procedures, including point-of-care testing made the diagnostics more accurate and enabled early diagnosis. New therapies are appearing in the medical field, including new bioavailability formulations like anti-inflammatory drugs lifitegrast and steroid/cyclosporine A, osmoprotectants such as trehalose-based tears, and bio-based drugs that are designed to regain homeostat Typically, such regenerative treatments as autologous serum, amniotic membrane extracts, and even gene therapy are catching fire in clinical trials. As artificial intelligence becomes an integral part of diagnostics and the personalized medicine approach, the care of DED is evolving into a more accurate and results-driven pattern.

Keywords: Dry Eye Disease, Tear Osmolarity, Ocular Inflammation, Anti-inflammatory Therapy, Lifitegrast, Autologous Serum, Osmoprotectants, Precision Medicine

1.2 Introduction

Known to physicians by the terms Dry Eye Disease (DED) or clinically termed as keratoconjunctivitis sicca, is a multifactorial chronic disease of the ocular surface presenting

with distress, visual and tear film instability. It is principally linked to osmolarity tears due to extremities and the inflammation of the ocular surface that destroys epithelial, alters the health of the neurosensory system, and sight (Craig et al., 2017). The report of DEWS II published by the Tear Film & Ocular Surface Society showed that an amount of 30 million citizens of the US and hundreds of millions of patients worldwide has DED (Stapleton et al., 2017).

Treatment DED was traditionally known as tear deficiency disorder which was solved through the application of lubricants and artificial tears. This approach however does not go to a great extent in correcting the inflammatory and homeostatic imbalances that represent the root cause of the disease. The relevance of inflammatory factors, invasion of immune cells, and oxidative stress was emphasized in promoting ocular surface damage by new evidence (Pflugfelder & Stern, 2020). The hyperosmolarity of tear film is also an indicator of disease course and, in fact a cause of disease development, which induces the activation of apoptosis and inflammation in epithelial cells as well as in the cornea (Bron et al., 2017).

Increasing technologies have have added more insight on to the complexity of DED. Newer methods such as in vivo confocal microscopy and optical coherence tomography (OCT) are capable of making high resolution images of ocular structures. On the contrary, the point-of-care equipment is able to monitor tear osmolarity and inflammation. These tools are used in early forecasts and personalized methods of treatment.

In the context of ongoing research efforts on biological therapies, regenerative medicine, and the application of artificial intelligence in diagnostic interventions, DED is now discussed as an immunoinflammatory disease rather than a single deficiency disease of the tears. In this review, the researcher aims to identify changes in knowledge about DED and to establish emerging areas of treatment that will provide better and more consistent management of this prevalent pathology.

1.3 Objective of paper

1. Understand inflammation's impact on tear film and ocular surface integrity.
2. Evaluate osmolarity-induced damage and role in disease pathogenesis.
3. Assess current and emerging therapies targeting Dry Eye Disease mechanisms.
4. Analyze technological advancements in diagnosis, including AI and biomarkers.

1.4. Pathophysiology of DED

The pathophysiology of Dry Eye Disease (DED) is complex, involving mechanisms of inflammation, osmolarity, and tear film instability, as well as meibomian gland dysfunction. It has been identified as a systemic and multifactorial disease, neither is localized problem of the ocular surface nor a problem affecting its visual, effect, resulting in decreased visual quality of life. TFOS DEWS II report provides a vicious circle: hyperosmolarity of the tear film triggers an inflammatory process, which, in turn, weakens the tear film and the ocular surface (Craig et al., 2017).

1.4.1 Inflammation

DED inflammation refers to innate and adaptive immunity. Epithelial cells respond to hyperosmolarity by secreting proinflammatory cytokines IL-1 connected with an interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF- Alpha), and interleukin-6 (IL-6). These mediators stimulate the activation of antigen-presenting cells, encourage T-cell infiltration and additionally release release matrix metalloproteinases (MMPs), specifically MMP-9whichwhich the cause destruction of the extracellular matrix and harm to epithelial cells (Bron et al., 2017; Pflugfelder & Stern, 2020).

1.4.2 Osmolarity

Tear film instability is the reason behind the variation in symptoms and visual disturbances in DED. The tear film consists of a lipid film, an aqueous film, and a mucin film. The deficiency of lipidacrimia and mucin can contribute to the deterioration of any of its layers, which subsequently applies to the abnormal tear break-up time (TBUT) and epithelial stress. The device called lacrimal single units (lacrimal glands integrated with the meibomian glands, the ocular surface, and the associated nervous system) causes homeostasis due to their integrity (Craig et al., 2017).

1.4.3 Tear Film Instability and Homeostasis

Instability in tear film causes symptom fluctuation and also induces a visual disturbance in DED. The tear film is made up of a mucin layer, an aqueous layer as well as a superficial lipid layer. A reduction in lipid secretion and a deficiency of the mucin can result in an impairment in any of its layers, e.g., abnormal tear break-up time (TBUT) and epithelial

stress. Single-unit functional integrity of lacrimal (integrity of lacrimal glands, meibomian glands, ocular surface, and their related nervous system) contributes to homeostasis (Craig et al., 2017).

1.4.4 Meibomian Gland Dysfunction

Meibomian Gland Dysfunction (MGD) constitutes an important contributor of evaporative DED. Poor lipid secretion, elevated evaporation and inflammation are caused by blocked MGD. The morphological changes are visible with infrared meibography and confocal microscopy: fall and atrophy of glands. MGD synthesizes inflammatory cytokines, which result in the transformation of gland ducts through keratinization to promote the dysfunctional process even further and destabilize the tear film (Nelson et al., 2011).

1.5. Risk Factors and Classification

The etiology of DED is multifactorial and is systemically caused by external factors of the environment, internal genuine conditions of the system, drugs, hormonal status and age. It is important that these risk factors be identified to help prevent, detect at an early stage and treat the disease accordingly.

1.5.1 Environmental and Lifestyle Factors

One of the reasons of DED is the modern lifestyle. Overusing the digital screens slows down the frequency of blinking, which thus causes people to lose tears. Tear film instability may be exacerbated by exposure to air conditioners, low-humidity environments, smoke, and pollutants. Wearing contact lenses is also associated with mechanical irritation and disruption of the tear film. Lifestyle changes are an essential preventive technique when a lack of proper workplace ergonomics escalates globally (Uchino et al., 2014).

1.5.2 Systemic Diseases and Medications

Diseases like Sjögren's syndrome, rheumatoid arthritis, diabetes mellitus, thyroid disorder, and rosacea are considered to have a strong relationship with DED. Sjögren syndrome is an autoimmune disease that affects lacrimal glands, leading to severe aqueous-deficient DED. The drugs that reduce the production or quality of tears include antihistamine drugs, beta-

blockers, antidepressants, and diuretics. The use of chemotherapeutic agents may also worsen the DED symptoms as it leads to damage to glands (Gayton, 2009).

1.5.3 Hormonal and Age-Related Influences

The lacrimal and meibomian gland function is altered due to hormonal changes, especially in postmenopausal women. The expression of estrogen and androgen has an effect on the secretion of lipids and the content of the tear film. As one age, there is a decline in glandular secretion, a reduction in the rate of blinking, and an increase in oxidative stress, all of which make old persons particularly prone to the risk of DED (Sullivan et al., 2002). The most common forms of DED include aqueous-deficient and evaporative DED, although some individuals have both types. This typing is used to select the proper diagnostic and therapeutic measures based on the mechanism.

1.6 Diagnostic Advances

The standard procedures for assessing DED include patient-reported symptoms and objective measurements. The most popular questionnaires are the Ocular Surface Disease Index (OSDI), the Standard Patient Evaluation of Eye Dryness (SPEED), and the Dry Eye Questionnaire (DEQ-5). The instruments are employed to gauge the level of discomfort, the rate of the symptoms as well as their effect on the daily life. Clinical assessment is done by measuring tear break-up time (TBUT), Schirmer-test, fluorescein stain, and by examination of the Meibomian glands. But there is one fairly strong but non-descript barrier between the correlation of signs and symptoms. Therefore, clinical examination is the foundation but it should be supported by developed techniques so as to attain high degree of diagnosis.

1.6.1 Clinical Evaluation and Symptom Scoring

Symptoms patient-reported and objective testing are usual elements of clinical assessment of DED. Some of the typical questionnaires include Ocular Surface Disease Index (OSDI), Standard Patient Evaluation of Eye Dryness (SPEED), and Dry Eye Questionnaire (DEQ-5). The scales are adopted to determine the degree of pain, the symptom frequency, and their effects on the quality of life. Clinical signs are determined using tear break-up time (TBUT), Schirmer test, fluorescein staining and examination of meibomian glands. However, there is just one rather strong obstacle, but it is a weak correlation of signs and symptoms. Such is why clinical assessment forms the basis, but at the same time, the standards of diagnosis need to be increased and this can only occur with incorporations of more advanced techniques.

1.6.2 Biomarker-Based Testing

The advancement of molecular diagnostics has enabled the identification of specific biomarkers associated with DED. A crucial indicator is tear film osmolarity, which is measured using a device such as the TearLab Osmolarity System. A value above 308 mOsm/L indicates that the person may be experiencing dry eye. Higher concentrations of matrix metalloproteinase-9 (MMP-9), as assessed by the Inflammation. Dry test indicate the presennce of ocular surface inflammation. Other potential future biomarkers that have been identified include interleukins (e.g., IL-6, IL-1β), lactoferrin, and cytokines, as they are involved in the inflammatory cascade of DED. The tests assist in subtyping DED into aqueous-deficient versus evaporative subtypes. They also aid in defining an individual treatment plan.

1.6.3 Imaging Technologies (OCT, meibography, Confocal Microscopy)

The use of imaging devices has significantly enhanced the structural and functional study of the ocular surface. The height of the tear meniscus and the examination of the thickness of the corneal epithelium are conducted with the help of Optical Coherence Tomography (OCT). Meibography is a diagnostic method that gives a detailed visual representation of meibomian glands, which is vital in diagnosing Meibomian Gland Dysfunction (MGD), which in turn is the most common cause of evaporative DED. Gland dropout or atrophy can be observed using an infrared camera or non-contact meibography. In-vivo Confocal Microscopy (IVCM) presents the high-resolution imaging of nerves in the cornea, immune cell infiltrate, and goblet cell density, which provides the possibility to identify the subclinical signs of inflammation and neuropathic pain elements. These imaging techniques are objective, repeatable, and sound in clinical and research practice.

1.6.4 Emerging AI-Based and Home Monitoring Devices

Artificial intelligence (AI) is becoming an increasingly significant component of DED diagnostics. DL algorithms are being combined with imaging (including OCT and meibography) to automatically label disease stages, identify minor changes, and make predictions on future trends. AI helps improve diagnostic performance by reducing inter-observer variations. Additionally, portable tear osmolarity readers, as well as smartphone-driven imaging devices, are enabling patients to monitor their symptoms at home. Bright contact lenses and wearable sensors are also in the development phase as a method of continuously monitoring the composition of tears and the presence of environmental stimuli. Such innovations facilitate advance disease treatment and person-centered care.

1.7 Current and Emerging Therapies

Dry Eye Disease (DED) is a complex, multifactorial condition characterized by an unstable tear film, inflammation, and nerve hypersensitivity of the ocular surface. It has developed from curbing its treatment to symptomatic controls to curbing the pathophysiological processes that it specifically encounters. New pharmacological agents, regenerative therapies, dietary interventions, personalized medicine, and formulations are rewriting clinical and home-based practice DED treatment. The section discusses at length the new and recent therapeutic possibilities that promise to offer not only symptomatic relief but also long-term disease control.

The application of an anti-inflammatory agent is a fundamental strategy in the management of DED. The critical role of inflammation in the pathogenesis of DED, irrespective of the underlying type (aqueous deficient or evaporative), has been ranked among the highest attributed to inflammation. Persistent inflammation destroys the tear film, causing a break in the epithelial layer of the eye. Short-term flare-ups are usually treated with topical corticosteroids, such as loteprednol and fluorometholone. They provide rapid symptomatic relief by acting to inhibit pro-inflammatory cytokines such as IL-1 and TNF-alpha and by inhibiting immune cell infiltration.

Nevertheless, they have limitations when used over a long period because they have several adverse effects, including decreased intraocular pressure and an increased risk of glaucoma. Consequently, chronic treatment usually becomes dependent on steroid-sparing drugs. Cyclosporine A, also known as CSA, is a calcineurin inhibitor that prevents T-cell activation and alleviates inflammation on the ocular surface, making it one of the most commonly used immunomodulators. The CsA ophthalmic emulsion (e.g., Restasis) has been found to enhance the tear production and the density of the goblet cells of the conjunctiva. More recently, lifitegrast, an L-sheet 861, marketed as Xiidra, has been in the news as an agent that blocks T-cell adhesion and the release of cytokines. Both CsA and lifitegrast are licensed for use on a chronic basis and relieve patients for several weeks to months. Additional experimental drugs, such as resolvins, thymosin 8 (THP4), and interleukin blockers, are under clinical trials and are likely to have more specific anti-inflammatory, anti-inflammatory effects with fewer side effects.

Besides managing inflammation, it is also essential to safeguard the ocular surface against hyperosmolar stress. A relatively new group of additives, referred to as osmoprotectants, stabilizes the tear film and counteracts osmotic injury to the epithelial cells. A significant

characteristic of DED is hyperosmolarity, which causes apoptosis of epithelial epithelial cells and contributes to inflammatory pathologies. Compounds such as L-carnitine, erythritol, and trehalose act as osmoprotectants, as they equalize cellular osmotic pressure and scavenge reactive oxygen species. Synthetic tears and lubricating eye drops are becoming more common as they contain this ingredient. Optive (L-carnitine and erythritol) and Thealoz Duo (trehalose) products have already proven to be more effective in alleviating symptoms and signs of DED than ordinary lubricants. In addition, osmoprotectants, along with lipids, hyaluronic acid, or anti-inflammatory agents, form combinations that provide synergistic protection and prolonged comfort. Increased attention to the use of osmoprotective therapy can be considered the result of a broader recognition of DED as not only a problem of tear deficiency but also a symptom of cellular stress and epithelial barrier impairment.

Regenerative medicine is another potential area of DED treatment. These are in the form of biological therapies designed to restore or regenerate the ocular surface, as well as its natural ability to produce tears. One of the most promising representatives of this sort is the autologous serum eye drops (ASEDs). With high concentrations of growth factors, vitamins, and anti-inflammatory proteins, ASEDs resemble natural tears and support the recovery of corneal epithelium. They prove to be particularly efficient in their extreme and unresponsive forms, as seen in cases such as Sjögren syndrome or after LASIK, resulting in dry eye. Platelet-rich plasma (PRP) is another novel therapy that contains even greater amounts of healing factors and is administered similarly to ASEDs. There is also the application of amniotic membrane transplantation (AMT) in patients who have substantial damage to the ocular surface. The membrane also provides a biological scaffold, which facilitates epithelial regeneration and alleviates inflammation. It can be used as a patch (cryopreserved or dehydrated) or incorporated into a contact lens to facilitate application. Nevertheless, stem cell therapies, despite being in experimental phases, hold promise for producing cures for the disease by regenerating lacrimal gland functions as well as goblet cell populations. Studies on mesenchymal stem cells, induced pluripotent stem cells, and limbal epithelial stem cells are also underway and may alter how DED is treated in the future.

Diet and lifestyle considerations also play an imperative role in the control of DED, especially in mild-moderate cases. Omega-3 fatty acids (EPA and DHA) are nutritional supplements that enhance the anti-inflammatory actions of the meibomian gland. This is due to the ability of these fatty acids to lower IL-1 and TNF-α concentrations in the tear film, thereby enhancing tear quality. Several randomized controlled trials have been conducted to assess their effectiveness with mixed but largely successful results. Other supplements that

promote ocular health include vitamins A and D, as well as antioxidants such as lutein and zeaxanthin, which are commonly recommended. The modifiability of the environment, which can be as simple as using a humidifier, lowering screen time, practicing blinking exercises, and wearing wrap-around glasses, is based on reducing tear evaporation. Patients with Meibomian Gland Dysfunction (MGD) typically respond well to eye hygiene measures, such as warm compresses and lid scrubs. Inflammatory triggers can be further decreased by avoiding air pollutants, smoke, and allergens. Treatment based on lifestyle interventions is the foundation of treatment and can be readily used in conjunction with pharmacological treatment, leading to improved long-term outcomes.

Combination and personalized treatment will be the future of DED therapy. The homogeneousness of the treatment no longer fits because the disease is heterogeneous. Personalized medicine is based on the subtype of a disease diagnosed in a patient, the composition of the tear film, the patient's genetic profile, and the patient the patient's response to treatment. Tear osmolarity, MMP-9 testing, and meibography are diagnostic tests that can inform clinicians about intervention choices. For example, patients with MGD can be treated more effectively with lipid-based artificial tears, warm compresses, and intense pulsed light (IPL) therapy.

In contrast, those with aqueous deficiency can respond well to cyclosporine or duct plugs. Multi-modality treatments, e.g., treating the disease according to more than one disease mechanism, such as using cyclosporine in combination with lipid-based artificial tears and omega-3 supplements. Innovation in delivery systems, e.g., nano micelles and hydrogel-based carriers, to increase drug bioavailability and adherence to treatment in patients. Additionally, AI software and monitoring devices are becoming integral to treatment plans, providing real-time feedback and helping to monitor worsening symptoms. Patient management and adherence AI-enabled apps can remind patients to use eye drops, monitor blink rate, and identify environmental factors that trigger symptoms, thereby improving patient engagement and individualized care.

1.8. Challenges in DED Management

Along with the improvement in the treatment of Dry Eye Disease (DED), several obstacles still exist in the effective management of this condition. The first problem is patient adherence. The chronic nature of DED is widely underestimated by patients who stop taking medicines or do not adhere to lifestyle changes when the improvement in symptoms is slow or uneven. Complex treatment plans, such as using numerous eye drops, warm compresses, and dietary supplements, can also become a deterrent to long-term compliance. It thus

becomes essential to educate patients. To break the cycle of inflammation and surface damage, clinicians must provide clear instructions and realistic expectations while emphasizing the importance of consistent therapy.

There are also therapeutic constraints and side effects that can interfere with achieving the most appropriate results. Although anti-inflammatory drugs such as cyclosporine and lifitegrast are effective, they can induce burning, stinging, or blurred vision, which typically appears in the early weeks of application. Corticosteroids are relatively potent but dangerous to use long-term, as they put the person at risk of cataracts and raised intraocular pressure. Even artificial tears can be unsuitable for some patients owing to their preservatives, viscosity, or bad retention period. Additionally, most of the therapies are more palliative than curative, and they are partial when it comes to managing the symptoms. Access and cost are also issues, especially in lower-resource settings, where specialized testing and highly specialized therapies may be unavailable.

1.9. Future Directions in Research and Clinical Practice

The future of DED management lies in individualized and evidence-based, as well as biologically informed, treatment. Precision medicine and Genomics are emerging disciplines that promise to detect personal risk factors, including gene variations associated with inflammation, mucin production, or immune regulation. Incorporation of genomic information can make it possible, someday, to predict which individuals are at risk of developing severe DED and further design rate-preventive or targeted therapy.

Artificial Intelligence (AI) is poised to usher in a revolution in diagnosis and treatment. The deep learning framework, as well as other AI-based tools, are currently being used to read meibography, OCT, and confocal microscopy images with high accuracy. These models will be able to identify early symptoms and be more proactive and specific about DED care through real-time insights on minor changes and symptoms, allowing for more effective treatment before symptoms worsen. Mobile apps with AI capabilities that monitor blinking patterns, tear film quality, and environmental conditions are being developed, as are smart contact lenses. In the meantime, clinical trials test various novel agents, including neuroprotective agents, stem cell-based therapies, and biologics that target cytokines such as IL-17 and TNF-alpha. Nanocarriers and sustained-release systems are two innovative drug delivery methods that enhance bioavailability and reduce the frequency of dosing. The current pipeline of therapeutic pharmaceutical solutions reflects a growing recognition of DED as a systemic, dynamic condition that requires multifaceted, multilateral, and long-term management solutions.

1.10 Conclusion

Conclusively, Dry Eye Disease is a common and often undiagnosed condition that can severely affect the quality of life. Although recent breakthroughs in the field of diagnostics and therapeutics have led to better patient care, issues such as adherence, efficacy of drug treatments, and access persist. The integration of emerging technologies, including AI and genomics, with the concepts of patient-centered and individualized care and education is the future of DED management. As research and innovation continue, the next wave of precise, minimal-impact, and effective treatments is not far off. Once available, they will deliver long-term relief and better results to millions affected by this silent ocular epidemic.

References

1. Baudouin, C., Aragona, P., Messmer, E. M., Tomlinson, A., Calonge, M., Boboridis, K. G., ... & Geerling, G. (2016). The Role of Hyperosmolarity in the Pathogenesis and Management of Dry Eye Disease: Clinical Implications. *Ocular Surface, 14*(2), 169–181. https://doi.org/10.1016/j.jtos.2016.01.003

2. Bron, A. J., de Paiva, C. S., Chauhan, S. K., Bonini, S., Gabison, E. E., Jain, S., ... & Sullivan, D. A. (2017). TFOS DEWS II pathophysiology report. *Ocular Surface, 15*(3), 438–510. https://doi.org/10.1016/j.jtos.2017.05.011

3. Craig, J. P., Nichols, K. K., Akpek, E. K., Caffery, B., Dua, H. S., Joo, C. K., ... & Stapleton, F. (2017). TFOS DEWS II definition and classification report. *Ocular Surface, 15*(3), 276–283. https://doi.org/10.1016/j.jtos.2017.05.008

4. Gayton, J. L. (2009). Etiology, prevalence, and treatment of dry eye disease. *Clinical Ophthalmology, 3*, 405–412. https://doi.org/10.2147/OPTH.S5555

5. Kaido, M., Matsumoto, Y., Shigeno, Y., Ishida, R., Dogru, M., & Tsubota, K. (2012). Relationship between dry eye symptoms and quality of life. *Journal of Japanese Ophthalmology, 56*(4), 324–329. https://doi.org/10.1007/s10384-012-0143-9

6. Lemp, M. A., & Foulks, G. N. (2007, but still widely cited in later years). The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). *Ocular Surface, 5*(2), 75–92.

7. Messmer, E. M. (2015). The pathophysiology, diagnosis, and treatment of dry eye disease. *Dtsch Arztebl Int, 112*(5), 71–81. https://doi.org/10.3238/arztebl.2015.0071

8. Nelson, J. D., Craig, J. P., Akpek, E. K., Azar, D. T., Belmonte, C., Bron, A. J., ... & Sullivan, D. A. (2017). TFOS DEWS II introduction. *Ocular Surface, 15*(3), 269–275. https://doi.org/10.1016/j.jtos.2017.05.003

9. Pflugfelder, S. C., & de Paiva, C. S. (2017). The pathophysiology of dry eye disease: What we know and future directions for research. *Ocular Surface, 15*(2), 331–336. https://doi.org/10.1016/j.jtos.2016.12.003

10. Stapleton, F., Alves, M., Bunya, V. Y., Jalbert, I., Lekhanont, K., Malet, F., ... & Jones, L. (2017). TFOS DEWS II epidemiology report. *Ocular Surface, 15*(3), 334–365. https://doi.org/10.1016/j.jtos.2017.05.003